One VC Firm’s 5 Healthcare Predictions for 2024
Executives at LRVHealth expect to see a continued focus on generative AI, increased enrollment in Medicare Advantage and more in 2024.
Executives at LRVHealth expect to see a continued focus on generative AI, increased enrollment in Medicare Advantage and more in 2024.
As a possible recession looms, the unemployment rate will likely rise, meaning employers won’t have to work as hard to find workers. Therefore, they’ll likely be cutting down on the digital health companies they work with, and tech vendors will really have to prove their worth in reducing costs, one expert says.
The need for mental health services continues to strain the ability of the healthcare system to respond. New technologies are helping to improve patient access to care, and a panel at the MedCity INVEST conference in Chicago discussed the challenges and opportunities for these services.
Behavioral health will be a focus of discussion at the MedCity INVEST conference coming up March 28-30 at the Ritz Carlton hotel in Chicago. Register now for compelling content, networking opportunities and startup pitches across pharma tech, medtech, diagnostics, and digital health.
In a wide-ranging interview, the National Coordinator for Health IT Dr. Micky Tripathi discussed his career and how his varied experiences have expanded his perspective. He also spoke about ONC's plans for the future, which include "evangelizing" about the opportunities the federal interoperability rules will create for the industry.
Representatives from five health services startups will present their companies to three judges, followed by a Q&A. The judges for the health services track include: Cheryl Chang of BlueRun Ventures; Keith Figlioli of LRVHealth, and Steve Tolle of HLM Venture Partners.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
The MedCity INVEST conference, April 19-23, will include a new session called Ask the Investor. The goal is to provide a forum for healthcare startups to better understand investment strategies for different groups and to ask investors questions.